

## Mainstay Medical Announces Participation in 30<sup>th</sup> Annual Piper Jaffray Healthcare Conference

**Dublin – Ireland, 21 November 2018** – Mainstay Medical International plc (“**Mainstay**” or the “**Company**”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, announces that the Company will participate in the 30<sup>th</sup> Annual Piper Jaffray Healthcare Conference 27-29 November in New York. Jason Hannon, Chief Executive Officer, and Matthew Onaitis, Chief Financial Officer, will conduct 1x1 meetings with investors.

– End –

### About Mainstay

Mainstay is a medical device company focused on commercializing an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands, and is listed on the regulated market of Euronext Paris (MSTY.PA) and the ESM of Euronext Dublin (MSTY.IE).

### About Chronic Low Back Pain

One of the recognized root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilize the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition, and the resulting days lost from work, disability benefits and health resource utilization put a significant burden on individuals, families, communities, industry and governments.

Further information can be found at [www.mainstay-medical.com](http://www.mainstay-medical.com)

*CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.*

### PR and IR Enquiries:

#### **Consilium Strategic Communications (international strategic communications - business and trade media)**

Chris Gardner, Jessica Hodgson, Nicholas Brown

Tel: +44 203 709 5700 / +44 7921 697 654

Email: [mainstaymedical@consilium-comms.com](mailto:mainstaymedical@consilium-comms.com)

#### **FTI Consulting (for Ireland)**

Jonathan Neilan

Tel: +353 1 765 0886

Email: [jonathan.neilan@fticonsulting.com](mailto:jonathan.neilan@fticonsulting.com)

#### **NewCap (for France)**

Julie Coulot, Tristan Roquet Montégon

Tel: +33 1 44 71 20 40

Email: [jcoulot@newcap.fr](mailto:jcoulot@newcap.fr)

#### **AndreasBohne.Com/Kötting Consulting (for Germany)**

Andreas Bohne

Tel : +49 2102 1485368

Email : [abo@andreasbohne.com](mailto:abo@andreasbohne.com)

Wilhelm Kötting

Tel: +49 69 75913293

Email: [wkotting@gmail.com](mailto:wkotting@gmail.com)

**Investor Relations:**

**LifeSci Advisors, LLC**

Brian Ritchie

Tel: + 1 (212) 915-2578

Email: [britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)

**ESM Advisers:**

**Davy**

Fergal Meegan or Barry Murphy

Tel: +353 1 679 6363

Email: [fergal.meegan@davy.ie](mailto:fergal.meegan@davy.ie) or [barry.murphy2@davy.ie](mailto:barry.murphy2@davy.ie)